Sickle Cell Disease Study

Last updated: N/A
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sickle Cell Disease

Treatment

N/A

Clinical Study ID

TX264159
  • Ages 12-65
  • All Genders

Study Summary

Study of Oral medication in Patients with Sickle Cell Disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 12 to 65
  • Patient has a confirmed diagnosis of sickle cell disease
  • Patient has had at least 2 episodes of VOC in the past 12 months

Exclusion

Exclusion Criteria:

Study Design

Study Start date:
January 26, 2021
Estimated Completion Date:

Study Description

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral medication, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease.

Connect with a study center

  • Advanced Pharma - Miami

    Miami, Florida 33147
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.